LSV Asset Management Has $94.93 Million Stock Position in Charles River Laboratories International, Inc. $CRL

LSV Asset Management raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 59.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 475,900 shares of the medical research company’s stock after buying an additional 178,100 shares during the period. LSV Asset Management’s holdings in Charles River Laboratories International were worth $94,933,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its position in Charles River Laboratories International by 84.5% in the third quarter. Principal Financial Group Inc. now owns 104,719 shares of the medical research company’s stock valued at $16,384,000 after buying an additional 47,954 shares in the last quarter. Madison Asset Management LLC acquired a new stake in Charles River Laboratories International in the third quarter valued at approximately $1,935,000. JPMorgan Chase & Co. boosted its position in Charles River Laboratories International by 14.5% in the third quarter. JPMorgan Chase & Co. now owns 317,179 shares of the medical research company’s stock valued at $49,626,000 after buying an additional 40,073 shares in the last quarter. Penserra Capital Management LLC acquired a new stake in Charles River Laboratories International in the third quarter valued at approximately $533,000. Finally, Cooke & Bieler LP boosted its position in Charles River Laboratories International by 0.9% in the third quarter. Cooke & Bieler LP now owns 603,877 shares of the medical research company’s stock valued at $94,483,000 after buying an additional 5,100 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Weiss Ratings lowered shares of Charles River Laboratories International from a “sell (d)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. UBS Group raised their target price on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price target for the company. Finally, Robert W. Baird set a $213.00 price target on shares of Charles River Laboratories International in a research note on Friday, May 8th. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $207.69.

Charles River Laboratories International Price Performance

CRL stock opened at $160.76 on Friday. The company has a fifty day moving average price of $167.61 and a 200-day moving average price of $181.33. The company has a market capitalization of $7.74 billion, a P/E ratio of -42.76, a PEG ratio of 1.83 and a beta of 1.44. Charles River Laboratories International, Inc. has a 52-week low of $132.58 and a 52-week high of $228.88. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.10. The firm had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.